ストックスクリーナーアプリを入手
65.60
0.03%
-0.02
アフターアワーズ：
65.60
前日終値:
$65.62
開ける：
$66.45
24時間の取引高:
2.65M
Relative Volume:
1.39
時価総額：
$9.12B
収益：
$105.82M
当期純損益:
$-829.61M
株価収益率:
-9.5866
EPS:
-6.8429
ネットキャッシュフロー:
$-548.92M
1週間 パフォーマンス:
+1.45%
1か月 パフォーマンス:
-8.80%
6か月 パフォーマンス:
-1.69%
1年 パフォーマンス:
+16.48%
1日の値動き範囲:
$64.49
$66.91
1週間の範囲:
$64.25
$67.27
52週間の値動き範囲:
$54.30
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
65.60 | 8.99B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Wells Fargo | Overweight |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
CYTK4910847 Bond Profile: Coupon and Redemption - TradingView
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - uk.finance.yahoo.com
Cytokinetics (CYTK) Launches ASPEN-HCM Study to Evaluate Myqorzo in Obstructive Hypertrophic Cardiomyopathy - GuruFocus
Cytokinetics launches real-world study of heart drug MYQORZO - Investing.com
Cytokinetics Announces Start of ASPEN-HCM Real-World Study of MYQORZO in Symptomatic Obstructive HCM - Quiver Quantitative
Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy - TradingView
Equity in earnings of Cytokinetics, Incorporated – HAN:KK3A - TradingView
Form 4 Cytokinetics Inc For: 29 September By Investing.com - Investing.com Nigeria
Cytokinetics CEO Robert Blum sells $490,949 in stock - Investing.com
Cytokinetics Insider Sold Shares Worth $490,950, According to a Recent SEC Filing - marketscreener.com
At $65.46 a share, Cytokinetics (CYTK) CEO Robert Blum sold 7,500 shares after exercising options. - Stock Titan
Weekly Recap: MYQORZO US/Germany uptake and COMET/AMBER program updates - TradingView
Cytokinetics (CYTK) Insider Trading Activity 2026 $CYTK - MarketBeat
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference - Yahoo Finance
CYTK5615147 Bond Profile: Coupon and Redemption - TradingView
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance Singapore
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics at bernstein healthcare forum: push beyond first launch By Investing.com - Investing.com South Africa
Cytokinetics at bernstein healthcare forum: push beyond first launch - Investing.com
Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story? - Yahoo Finance
Cytokinetics Inc (CYTK) EVP Research & Development Fady Malik Se - GuruFocus
Form 4 Cytokinetics Inc For: 22 September - Investing.com India
Form 4 Cytokinetics Inc For: 22 September By Investing.com - Investing.com Canada
Cytokinetics EVP Fady Malik sells $239k in company stock - Investing.com
Cytokinetics EVP Fady Malik sells $239k in company stock By Investing.com - Investing.com Nigeria
Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years - Benzinga
Cytokinetics stock steadies after recent data and guidance updates - AD HOC NEWS
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Cytokinetics CEO, President & Director Robert Blum Sells 44% Of Holding - simplywall.st
Cytokinetics CEO Blum’s trust sells $6.7m in company shares By Investing.com - za.investing.com
Cytokinetics director Robert Landry sells $72,130 in shares - Investing.com
Cytokinetics CEO Blum’s trust sells $6.7m in company shares - Investing.com
Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Shares - GuruFocus
Trust tied to Cytokinetics (NASDAQ: CYTK) CEO moves to sell shares - Stock Titan
Family trust tied to Cytokinetics (NASDAQ: CYTK) CEO just sold about 98,000 shares - stocktitan.net
Cytokinetics at Morgan Stanley conference: launch gains and broader bets - Investing.com
Patient advocacy groups have until Oct. 2 to apply for heart disease outreach grants - Stock Titan
Cytokinetics, Incorporated rStock Price, RCYTK Price, Live Charts, and Marketcap - Coinbase
Cytokinetics director Robert Landry sells $74,660 in shares By Investing.com - Investing.com South Africa
Cytokinetics director Robert Landry sells $74,660 in shares - Investing.com
Cytokinetics (NASDAQ: CYTK) director plans 2,000-share Rule 144 sale - Stock Titan
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Cantor Fitzgerald reiterates Overweight on Cytokinetics stock By Investing.com - Investing.com Australia
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com Nigeria
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03 - marketscreener.com
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO |
Sep 28 '26 |
Sale |
65.46 |
7,500 |
490,950 |
278,544 |
| Malik Fady Ibraham | EVP Research & Development |
Sep 22 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
Sep 22 '26 |
Sale |
68.29 |
3,500 |
239,015 |
153,902 |
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):